Richard L. Tuttle
About
In The Last Decade
Richard L. Tuttle
24 papers receiving 516 citations
Peers
Comparison fields: 5 of 94
- Oncology 184
- Immunology 180
- Molecular Biology 174
- Pulmonary and Respiratory Medicine 110
- Organic Chemistry 94
Countries citing papers authored by Richard L. Tuttle
This map shows the geographic impact of Richard L. Tuttle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard L. Tuttle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard L. Tuttle more than expected).
Fields of papers citing papers by Richard L. Tuttle
This network shows the impact of papers produced by Richard L. Tuttle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard L. Tuttle. The network helps show where Richard L. Tuttle may publish in the future.
Co-authorship network of co-authors of Richard L. Tuttle
This figure shows the co-authorship network connecting the top 25 collaborators of Richard L. Tuttle. A scholar is included among the top collaborators of Richard L. Tuttle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard L. Tuttle. Richard L. Tuttle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 8 | |
| 3 | 31 | |
| 4 | 1 | |
| 5 | 21 | |
| 6 | 0 | |
| 7 | 5 | |
| 8 | 3 | |
| 9 | 72 | |
| 10 | 46 | |
| 11 | 70 | |
| 12 | Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule. | 12 |
| 13 | High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. | 21 |
| 14 | Interferon-alpha therapy of renal cancer. | 59 |
| 15 | In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice. | 10 |
| 16 | 89 | |
| 17 | 38 | |
| 18 | Mechanisms of antitumor action of Corynebacterium parvum: replicating short-lived T cells as the mediators of potentiated tumor-specific immunity. | 14 |
| 19 | 50 | |
| 20 | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.